#1 Clinical Trials Search in Europe

Dextromethadone Hydrochloride

Dextromethadone Hydrochloride, also known as REL-1017, is being studied in clinical trials for its potential to treat major depressive disorder (MDD) and restless legs syndrome (RLS). These trials aim to evaluate the drug’s efficacy, safety, and tolerability in patients who have not responded well to current treatments. The studies involve randomized, double-blind, placebo-controlled designs to assess the drug’s effects on symptoms, quality of life, and overall patient well-being.

Table of Contents

Introduction

DEXTROMETHADONE HYDROCHLORIDE, also known as REL-1017 or d-Methadone, is an investigational drug being studied for its potential to treat two distinct medical conditions: Major Depressive Disorder (MDD) and Restless Legs Syndrome (RLS). This article will provide an overview of the ongoing research into this promising medication based on recent clinical trials.[1][2]

DEXTROMETHADONE HYDROCHLORIDE for Major Depression

Major Depressive Disorder is a serious mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest in daily activities. DEXTROMETHADONE HYDROCHLORIDE is being investigated as a potential new treatment for patients with MDD who have not responded adequately to current antidepressant therapies.[1]

Key points about the research on DEXTROMETHADONE HYDROCHLORIDE for MDD include:

  • It is being studied as an adjunctive treatment, meaning it would be used in addition to existing antidepressant medications.
  • The drug is taken orally in tablet form.
  • The current clinical trial is testing a dosage of 75 mg per day for 28 days.
  • Researchers are primarily interested in how well the drug reduces depressive symptoms as measured by standardized rating scales.

DEXTROMETHADONE HYDROCHLORIDE for Restless Legs Syndrome

Restless Legs Syndrome is a neurological disorder that causes an irresistible urge to move the legs, often accompanied by uncomfortable sensations. It frequently disrupts sleep and can significantly impact quality of life. DEXTROMETHADONE HYDROCHLORIDE is also being studied as a potential treatment for moderate to severe RLS.[2]

Important aspects of the RLS research include:

  • The study is focusing on patients with primary RLS (not caused by another medical condition).
  • The dosage being tested is 25 mg per day, taken in the evening.
  • Researchers are looking at how the drug affects RLS symptoms, sleep quality, and overall quality of life.
  • The study includes objective measurements of sleep and leg movements using specialized equipment.

Drug Information

DEXTROMETHADONE HYDROCHLORIDE is a chemical compound related to methadone but with some important differences. Here’s what we know about the drug:

  • It is taken orally as a tablet.
  • The drug is being developed by a company called MGGM LLC.
  • It is not yet approved for general use and is only available through clinical trials.
  • The exact mechanism of how it may help with depression or RLS is still being studied.

Potential Benefits

If proven effective, DEXTROMETHADONE HYDROCHLORIDE could offer several potential benefits:

  • For depression: It may help patients who haven’t responded well to other antidepressants, potentially reducing symptoms and improving quality of life.
  • For RLS: It could provide relief from the uncomfortable sensations and urge to move, potentially improving sleep and overall well-being.
  • The oral tablet form makes it easy to administer.
  • The once-daily dosing schedule could be convenient for patients.

Safety and Side Effects

As DEXTROMETHADONE HYDROCHLORIDE is still in the research phase, its full safety profile is not yet known. The ongoing clinical trials are carefully monitoring for potential side effects and safety concerns. Some points to note:

  • Patients with certain medical conditions or taking specific medications are excluded from the trials to minimize risks.
  • The studies are closely monitoring heart rhythm, liver function, and kidney function.
  • Potential interactions with other medications are being evaluated.
  • The trials include regular check-ups and tests to ensure participant safety.

Ongoing Research

The clinical trials for DEXTROMETHADONE HYDROCHLORIDE are still in progress. Here’s what you should know about the current state of research:

  • The MDD study is a Phase 3 trial, which is typically one of the final stages before seeking regulatory approval.
  • The RLS study is a Phase 2 trial, which aims to gather more data on efficacy and optimal dosing.
  • Both studies are randomized, double-blind, and placebo-controlled, which are considered the gold standard for medical research.
  • Results from these trials will help determine whether DEXTROMETHADONE HYDROCHLORIDE is safe and effective enough to become an approved treatment option.

It’s important to note that while the initial research is promising, DEXTROMETHADONE HYDROCHLORIDE is not yet available as a treatment option outside of clinical trials. Patients interested in learning more should speak with their healthcare providers about current treatment options and the possibility of participating in clinical research.

Aspect MDD Trial RLS Trial
Study Type Phase 3, randomized, double-blind, placebo-controlled Phase 2, randomized, double-blind, placebo-controlled
Condition Major Depressive Disorder Restless Legs Syndrome
Main Objective Evaluate efficacy of REL-1017 as adjunctive treatment Investigate efficacy of REL-1017 in moderate to very severe RLS
Primary Endpoint Change in MADRS10 total score from baseline to Day 28 Percentage of responders (≥50% reduction in IRLS-RS score) at Day 30
Dosage Up to 75 mg daily 25 mg daily at 6 pm
Treatment Duration 28 days 30 days
Key Assessments MADRS, CGI-S, DSST, ASEX, SDS, HAM-A IRLS-RS, actigraphy, polysomnography, CGI-Efficacy index
Safety Monitoring Adverse events, vital signs, ECG, laboratory tests, C-SSRS Adverse events, ECG, laboratory tests

FAQ

  • What is Dextromethadone Hydrochloride? Dextromethadone Hydrochloride, also known as REL-1017, is an investigational drug being studied for its potential to treat major depressive disorder (MDD) and restless legs syndrome (RLS). It is a new compound that researchers hope may provide relief for patients who haven't responded well to existing treatments.
  • What conditions are being studied in these clinical trials? The clinical trials are focusing on two main conditions: major depressive disorder (MDD) in patients who have not responded adequately to current antidepressant treatments, and moderate to very severe restless legs syndrome (RLS) with periodic limb movements.
  • How is the drug administered in these trials? In both trials, Dextromethadone Hydrochloride is administered orally in tablet form. For the MDD trial, the maximum daily dose is 75 mg, while for the RLS trial, patients receive 25 mg daily, taken at 6 pm.
  • How long do the treatment periods last in these trials? The treatment period for the MDD trial lasts 28 days, while the RLS trial has a treatment period of 30 days. Both trials include additional screening and follow-up periods.
  • What are the main outcomes being measured in these trials? For the MDD trial, the main outcome is the change in depression severity as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). For the RLS trial, the primary outcome is the percentage of patients who respond to treatment, defined as a 50% or greater reduction in RLS symptoms as measured by the International RLS Rating Scale (IRLS-RS).

Ongoing Clinical Trials on Dextromethadone Hydrochloride

  • Study on the Effects of Dextromethadone Hydrochloride for Patients with Moderate to Very Severe Restless Legs Syndrome

    Not yet recruiting

    1
    Investigated drugs:
    Italy

  • Study on the Effectiveness and Safety of REL-1017 for Patients with Major Depression Who Have Not Responded to Current Treatment

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Dextromethadone Hydrochloride (REL-1017): An investigational drug being studied for its potential to treat major depressive disorder and restless legs syndrome.
  • Major Depressive Disorder (MDD): A mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities, which significantly impairs daily functioning.
  • Restless Legs Syndrome (RLS): A neurological disorder characterized by an irresistible urge to move the legs, often accompanied by uncomfortable sensations, typically occurring at night or during periods of rest.
  • Montgomery-Åsberg Depression Rating Scale (MADRS): A commonly used scale to measure the severity of depressive episodes in patients with mood disorders.
  • International RLS Rating Scale (IRLS-RS): A scale used to assess the severity of restless legs syndrome symptoms.
  • Placebo: An inactive substance or treatment used in clinical trials to compare the effects of the investigational drug against a non-active alternative.
  • Double-blind study: A type of clinical trial where neither the participants nor the researchers know who is receiving the active treatment and who is receiving the placebo.
  • Efficacy: The ability of a treatment to produce the desired beneficial effect.
  • Adjunctive treatment: An additional treatment used together with the primary treatment to enhance its effectiveness.
  • Periodic Limb Movements: Repetitive cramping or jerking of the legs during sleep, often associated with restless legs syndrome.
  • Polysomnography (PSG): A comprehensive sleep study that records brain waves, blood oxygen levels, heart rate, breathing, and eye and leg movements during sleep.
  • Actigraphy: A non-invasive method of monitoring human rest/activity cycles, typically using a small wearable device.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-rel-1017-for-patients-with-major-depression-who-have-not-responded-to-current-treatment/
  2. http://clinicaltrials.eu/trial/study-on-the-effects-of-dextromethadone-hydrochloride-for-patients-with-moderate-to-very-severe-restless-legs-syndrome/